ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia

The hallmarks of cancer

Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058

The Bcl-2 apoptotic switch in cancer development and therapy

Adams, J. M., & Cory, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210220 · Cited by 2,256

GenePattern 2.0

Reich, M. M., Liefeld, T., Gould, J., Lerner, J., Tamayo, P., & Mesirov, J. P. (2006) · Nature Genetics · doi:10.1038/ng0506-500 · Cited by 2,053

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992

Acute lymphoblastic leukaemia

Pui, C.-H., Robison, L. L., & Look, A. T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60457-2 · Cited by 1,564

Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia

Ferrando, A. A., Neuberg, D. S., Staunton, J. E., Loh, M. L., Huard, C., Raimondi, S. C., Behm, F. G., Pui, C., Downing, J. R., Gilliland, D. G., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00018-1 · Cited by 1,130

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia

Coustan‐Smith, E., Mullighan, C. G., Onciu, M. M., Behm, F. G., Raimondi, S. C., Pei, D., Cheng, C., Su, X., Rubnitz, J. E., Basso, G., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70314-0 · Cited by 1,012

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

Roberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., Carney, D. A., He, S., Huang, D. C. S., Xiong, H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7898 · Cited by 855

Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen

Zhang, X., Li, J., Jin, J., & Yu, W. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03902-9 · Cited by 30

Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples

Lu, B. Y., Thanawala, S. U., Zochowski, K. C., Burke, M. J., Carroll, W. L., & Bhatla, T. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1110747 · Cited by 30

BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis

Heinicke, U., Haydn, T., Kehr, S., Vogler, M., & Fulda, S. (2018) · Oncogene · doi:10.1038/s41388-018-0212-5 · Cited by 29

Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T‐cell lymphoblastic leukemia

Zappone, E., Cencini, E., Defina, M., Sicuranza, A., Gozzetti, A., Ciofini, S., Raspadori, D., Mecacci, B., & Bocchia, M. (2020) · Clinical Case Reports · doi:10.1002/ccr3.3041 · Cited by 29

Design of a Comprehensive Fluorescence in Situ Hybridization Assay for Genetic Classification of T-Cell Acute Lymphoblastic Leukemia

Starza, R. L., Pierini, V., Pierini, T., Nofrini, V., Matteucci, C., Arniani, S., Moretti, M., Fernandez, A. G. L., Pellanera, F., Giacomo, D. D., et al. (2020) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2020.02.004 · Cited by 28

Comparison of Early T-Cell Precursor and Non-ETP Subtypes Among 122 Chinese Adults With Acute Lymphoblastic Leukemia

Zhang, Y., Qian, J., Zhou, Y., Huang, X., Li, J., Li, X., Li, C., Wang, H., Lou, Y., Meng, H., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01423 · Cited by 27

MEF2C opposes Notch in lymphoid lineage decision and drives leukemia in the thymus

Canté-Barrett, K., Meijer, M. T., Cordo’, V., Hagelaar, R., Yang, W., Yu, J., Smits, W. K., Nulle, M. E., Jansen, J. P., Pieters, R., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.150363 · Cited by 28

Venetoclax Induces Cardiotoxicity through Modulation of Oxidative-Stress-Mediated Cardiac Inflammation and Apoptosis via NF-κB and BCL-2 Pathway

Alasmari, A. F., Alghamdi, A., Ali, N., Almeaikl, M. A., Hakami, H. M., Alyousef, M. K., Alswayyed, M., Alharbi, M., Alqahtani, F., Alasmari, F. F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116260 · Cited by 27

Early T-Cell Precursor ALL and Beyond: Immature and Ambiguous Lineage T-ALL Subsets

Genescà, E., & Starza, R. L. (2022) · Cancers · doi:10.3390/cancers14081873 · Cited by 26

Killing Two Cells with One Stone: Pharmacologic BCL-2 Family Targeting for Cancer Cell Death and Immune Modulation

Ludwig, L. M., Nassin, M. L., Hadji, A., & LaBelle, J. L. (2016) · Frontiers in Pediatrics · doi:10.3389/fped.2016.00135 · Cited by 25

Relapsed/Refractory ETP‐ALL Successfully Treated With Venetoclax and Nelarabine as a Bridge to Allogeneic Stem Cell Transplant

McEwan, A. K., Pitiyarachchi, O., & Viiala, N. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000379 · Cited by 25

BCL2 Inhibitor (ABT-737): A Restorer of Prednisolone Sensitivity in Early T-Cell Precursor-Acute Lymphoblastic Leukemia with High MEF2C Expression?

Kawashima‐Goto, S., Imamura, T., Tomoyasu, C., Yano, M., Yoshida, H., Fujiki, A., Tamura, S., Osone, S., Ishida, H., Morimoto, A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132926 · Cited by 25

Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party

Bazarbachi, A. H., Hamed, R. A., Labopin, M., Afanasyev, B. V., Hamladji, R., Beelen, D. W., Eder, M., Scheid, C., Wu, D., Bunjes, D. W., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0702-2 · Cited by 25

Glucocorticoid Therapy in Acute Lymphoblastic Leukemia: Navigating Short-Term and Long-Term Effects and Optimal Regimen Selection

Pourhassan, H., Murphy, L. A., & Aldoss, I. T. (2024) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-024-00735-w · Cited by 24

Multi-omic approaches to improve outcome for T-cell acute lymphoblastic leukemia patients

van der Zwet, J. C. G., Cordo’, V., Canté-Barrett, K., & Meijerink, J. P. P. (2019) · Advances in Biological Regulation · doi:10.1016/j.jbior.2019.100647 · Cited by 24

High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia

Oikonomou, A., Valsecchi, L., Quadri, M., Watrin, T., Scharov, K., Procopio, S., Tu, J., Vogt, M., Savino, A. M., Silvestri, D., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115809 · Cited by 23

Differential Co-expression and Regulatory Network Analysis Uncover the Relapse Factor and Mechanism of T Cell Acute Leukemia

Luo, M., Zhang, Q., Xia, M., Hu, F., Ma, Z., Chen, Z., & Guo, A. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.05.003 · Cited by 23

MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated withCDKN1Bdeletions and a poor response to glucocorticoid therapy

Colomer‐Lahiguera, S., Pisecker, M., König, M., Nebral, K., Pickl, W. F., Kauer, M. O., Haas, O. A., Ullmann, R., Attarbaschi, A., Dworzak, M. N., et al. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1312383 · Cited by 21

The spleen as a sanctuary site for residual leukemic cells following ABT-199 monotherapy in ETP-ALL

Grande, A. D., Peirs, S., Donovan, P. D., Trimpont, M. V., Morscio, J., Lintermans, B., Reunes, L., Vandamme, N., Goossens, S., Nguyen, H. A. T., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004177 · Cited by 21

Emerging biological therapies to treat acute lymphoblastic leukemia

Huguet, F., & Tavitian, S. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1257606 · Cited by 20

Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party

Bazarbachi, A. A., Labopin, M., Angelucci, E., Gülbaş, Z., Özdoğu, H., Arat, M., Rosa, L. D., Pastano, R., Pioltelli, P. E., Montserrat, R., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.01.003 · Cited by 19

Downregulation of PUMA underlies resistance to FGFR1 inhibitors in the stem cell leukemia/lymphoma syndrome

Liu, Y., Cai, B., Chong, Y., Zhang, H., Kemp, C.-A., Lu, S., Chang, C.-S., Ren, M., Cowell, J. K., & Hu, T. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03098-1 · Cited by 18

Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterations

Ferrari, A., Cangini, D., di Rorà, A. G. L., Condorelli, A., Pugliese, M., Schininà, G., Cosentino, S., Fonzi, E., Domizio, C., Simonetti, G., et al. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1165308 · Cited by 18

CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration

Walker, K. L., Rinella, S., Hess, N. J., Turicek, D. P., Kabakov, S. A., Zhu, F., Bouchlaka, M. N., Olson, S. L., Cho, M. M., Quamine, A. E., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1910684 · Cited by 19

Overcoming Steroid Resistance in T Cell Acute Lymphoblastic Leukemia

Goossens, S., & Vlierberghe, P. V. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002208 · Cited by 18

Venetoclax‐based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia

Canaani, J., Frisch, A., Pollyea, D. A., Schwartz, M., Aumann, S., Ganzel, C., Haran, A., Even‐Zohar, N. G., Shaulov, A., Vainstein, V., et al. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14015 · Cited by 17

Recent advances in T-cell lymphoid neoplasms

Bigas, A., Rodríguez‐Sevilla, J. J., Espinosa, L., & Gallardo, F. (2021) · Experimental Hematology · doi:10.1016/j.exphem.2021.12.191 · Cited by 17

Inhibition of InsP3R with Xestospongin B Reduces Mitochondrial Respiration and Induces Selective Cell Death in T Cell Acute Lymphoblastic Leukemia Cells

Cruz, P., Ahumada-Castro, U., Bustos, G., Molgó, J., Sauma, D., Lovy, A., & Cárdenas, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020651 · Cited by 17

Inside the biology of early T-cell precursor acute lymphoblastic leukemia: the perfect trick

Tarantini, F., Cumbo, C., Anelli, L., Zagaria, A., Specchia, G., Musto, P., & Albano, F. (2021) · Biomarker Research · doi:10.1186/s40364-021-00347-z · Cited by 16

Design and synthesis of various quinizarin derivatives as potential anticancer agents in acute T lymphoblastic leukemia

Hu, X., Cao, Y., Yin, X. Y., Zhu, L., Chen, Y., Wang, W., & Hu, J. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.02.041 · Cited by 16

Preferential targeting of MCL-1 by a hydrocarbon-stapled BIM BH3 peptide

Hadji, A., Schmitt, G. K., Schnorenberg, M. R., Roach, L. E., Hickey, C. M., Leak, L. B., Tirrell, M., & LaBelle, J. L. (2019) · Oncotarget · doi:10.18632/oncotarget.27262 · Cited by 16

CBFA2T3-GLIS2-dependent pediatric acute megakaryoblastic leukemia is driven by GLIS2 and sensitive to navitoclax

Neault, M., Lebert‐Ghali, C., Fournier, M., Capdevielle, C., Garfinkle, E. A. R., Obermayer, A., Cotton, A., Boulay, K., Sawchyn, C., St-Amand, S., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113084 · Cited by 15

Homoharringtonine synergizes with venetoclax in early T cell progenitor acute lymphoblastic leukemia: Bench and bed

Suo, S., Sun, S., Nguyen, L. X. T., Qian, J., Li, F., Zhao, D., Yu, W., Lou, Y., Zhu, H., Tong, H., et al. (2024) · Med · doi:10.1016/j.medj.2024.07.018 · Cited by 15

ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells

Valdez, B. C., Murray, D. L., Yuan, B., Nieto, Y. L., Popat, U., & Andersson, B. S. (2022) · Oncotarget · doi:10.18632/oncotarget.28193 · Cited by 15

Overcoming Steroid Resistance in Pediatric Acute Lymphoblastic Leukemia—The State-of-the-Art Knowledge and Future Prospects

Kośmider, K., Karska, K., Kozakiewicz, A., Lejman, M., & Zawitkowska, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073795 · Cited by 15

LMO2 Oncoprotein Stability in T-Cell Leukemia Requires Direct LDB1 Binding

Layer, J. H., Alford, C. E., McDonald, W. H., & Davé, U. P. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00901-15 · Cited by 14

Prevention and treatment of relapse after stem cell transplantation with immunotherapy

Gökbuget, N., Canaani, J., Nagler, A., Bishop, M., Kröger, N. M., & Avigan, D. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0232-3 · Cited by 14

Targeting Leukemia-Initiating Cells and Leukemic Niches: The Next Therapy Station for T-Cell Acute Lymphoblastic Leukemia?

Zhang, Z., Yang, K., & Zhang, H. (2022) · Cancers · doi:10.3390/cancers14225655 · Cited by 16

Revisiting β‐Catenin Signaling in T‐Cell Development and T‐Cell Acute Lymphoblastic Leukemia

Bigas, A., Guillén, Y., Schoch, L., & Arambilet, D. (2019) · BioEssays · doi:10.1002/bies.201900099 · Cited by 14

Targeting N-cadherin (CDH2) and the malignant bone marrow microenvironment in acute leukaemia

Parker, J., Hockney, S., Blaschuk, O. W., & Pal, D. (2023) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2023.13 · Cited by 14

Interleukin-7 signaling as a therapeutic target in acute lymphoblastic leukemia

Savino, A. M., & Izraeli, S. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1292121 · Cited by 14

Novel strategies to prevent and overcome relapse after allogeneic hematopoietic cell transplantation in acute lymphoblastic leukemia

Hodroj, M. H., Dalle, I. A., Moukalled, N. M., Cheikh, J. E., Mohty, M., & Bazarbachi, A. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1191912 · Cited by 13

PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemia

Shah, K., Nasimian, A., Ahmed, M., Ashiri, L. A., Denison, L., Sime, W., Bendak, K., Kolosenko, I., Siino, V., Levander, F., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00914-7 · Cited by 13

Daratumumab and venetoclax combined with CAGE for late R/R T-ALL/LBL patients: Single-arm, open-label, phase I study

Shi, H., Yang, F., Cao, M., Xu, T., Zheng, P., Guo, Y., Su, G., Feng, S., Li, R., Liu, R., et al. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05775-z · Cited by 13

Azacitidine in Combination with Venetoclax Maintenance Post-allogeneic Hematopoietic Stem Cell Transplantation in T Cell Acute Lymphoblastic Leukemia

Hassan, M. A., Moukalled, N. M., Cheikh, J. E., Bazarbachi, A. A., & Dalle, I. A. (2023) · Clinical Hematology International · doi:10.1007/s44228-022-00019-1 · Cited by 13

Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia

Summers, R. J., Jain, J., Vasileiadi, E., Smith, B. M., Chimenti, M. L., Yeung, T. Y., Kelvin, J., Wang, X., Frye, S. V., Earp, H. S., et al. (2022) · Cancers · doi:10.3390/cancers14246142 · Cited by 12

Venetoclax and Decitabine in Pediatric Refractory T-cell Lymphoblastic Lymphoma

Baig, M. U., Rytting, M., Roth, M. E., Morani, A. C., Núnêz, C., Lin, P., & Cuglievan, B. (2021) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000002050 · Cited by 12

Lipase-triggered drug release from BCL2 inhibitor ABT-199-loaded nanoparticles to elevate anti-leukemic activity through enhanced drug targeting on the mitochondrial membrane.

Liang, B., Jiang, D., Pan, L., Xiong, F., Feng, S., Wu, S.-H., Ye, H.-G., Yu, Z.-J., Shi, C.-C., & Gao, S.-M. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.04.005 · Cited by 13

Discovery and identification of a novel small molecule BCL-2 inhibitor that binds to the BH4 domain

Zhou, J., Yang, R., Chang, J., Song, J., Fan, Z., Zhang, Y., Lu, C.-H., Jiang, H., Zheng, M.-Y., & Zhang, S. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00936-0 · Cited by 13

Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia

Mezzatesta, C., & Bornhauser, B. C. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00040 · Cited by 12

Antileukemia efficacy of the dual BCL2/BCL-XL inhibitor AZD0466 in acute lymphoblastic leukemia preclinical models

Kannan, S., Li, Y., Baran, N., Yang, X., Ghotbaldini, S., Tatarata, Q. Z., Yoshimura, S., Li, Z., Hsiao, Y.-C., Balachander, S. B., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013423 · Cited by 12

Venetoclax: A Review in Previously Untreated Chronic Lymphocytic Leukaemia

Blair, H. A. (2020) · Drugs · doi:10.1007/s40265-020-01433-6 · Cited by 11

CASZ1 upregulates PI3K-AKT-mTOR signaling and promotes T-cell acute lymphoblastic leukemia

Cardoso, B. A., Duque, M., Gírio, A., Fragoso, R., Oliveira, M. L., Allen, J., Martins, L. R., Correia, N., Silveira, A. B., Veloso, A. B., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.282854 · Cited by 10

Dual Bcl-XL /Bcl-2 inhibitors discovered from DNA-encoded libraries using a fragment pairing strategy

Daguer, J., Gonse, A., Shchukin, Y., Soler, L. F., Barluenga, S., & Winssinger, N. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116282 · Cited by 10

The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review

Prejzner, W., Piekoś, O., Bełdzińska, K., Sadowska‐Klasa, A., Zarzycka, E., Bieniaszewska, M., Lewandowski, K. C., & Zaucha, J. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1228481 · Cited by 10

The Role of BH3-Mimetic Drugs in the Treatment of Pediatric Hepatoblastoma

Lieber, J., Armeanu–Ebinger, S., & Fuchs, J. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16024190 · Cited by 10

A critical regulator of Bcl2 revealed by systematic transcript discovery of lncRNAs associated with T-cell differentiation

Saadi, W., Kermezli, Y., Dao, L. T. M., Mathieu, È.-L., Santiago‐Algarra, D., Manosalva, I., Torres, M., Belhocine, M., Pradel, L. C., Loriod, B., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41247-5 · Cited by 10

Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax

Li, D., Yuan, Y., Chen, M., Lin, Z., Zhao, M., Shi, L., Li, M., Ye, D., Yue, C., He, X., et al. (2024) · Clinical Epigenetics · doi:10.1186/s13148-024-01658-2 · Cited by 9

Failure of tofacitinib to achieve an objective response in a DDX3X-MLLT10 T-lymphoblastic leukemia with activating JAK3 mutationsPreprint

Wong, J., Wall, M., Corboy, G., Taubenheim, N., Gregory, G. P., Opat, S., & Shortt, J. (2020) · Molecular Case Studies · doi:10.1101/mcs.a004994 · Cited by 9

Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents

Maly, J. J., & Blachly, J. S. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0299-0 · Cited by 8

Venetoclax with CAG regimen for early T-cell precursor acute lymphoblastic leukemia: a case report and literature review

Zhao, Y., Jiang, S., Tang, Y., & Zhao, L. (2023) · International Journal of Hematology · doi:10.1007/s12185-023-03623-w · Cited by 8

Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemia

Kelvin, J., Chimenti, M. L., Zhang, D. Y., Williams, E. K., Moore, S. G., Humber, G. M., Baxter, T. A., Birnbaum, L. A., Qui, M., Zecca, H., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.045 · Cited by 8

The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions

Miller, L. H., Maxa, K. L., Winter, S. S., & Gossai, N. P. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2271662 · Cited by 8

Co-operation of ABT-199 and gemcitabine in impeding DNA damage repair and inducing cell apoptosis for synergistic therapy of T-cell acute lymphoblastic leukemia

Xiufeng, Z., Haijun, Z., Bi, S., Manman, D., Zhou, Y., Yu, L., Zhihong, F., & Xu, B. (2018) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000702 · Cited by 8

Repurposing anthelmintic agents to eradicate resistant leukemia

Mezzatesta, C., Abduli, L., Guinot, A., Eckert, C., Schewe, D. M., Zaliova, M. K., Vinti, L., Marovca, B., Tsai, Y.-C., Jenni, S., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0339-9 · Cited by 8

Treating adults with acute lymphocytic leukemia: new pharmacotherapy options

Thomas, X., & Jeune, C. L. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1250884 · Cited by 8

Novel strategy for rapid functional in vivo validation of oncogenic drivers in haematological malignancies

Pieters, T., T’Sas, S., Demoen, L., Almeida, A., Haenebalcke, L., Matthijssens, F., Lemeire, K., D’Hont, J., Rockeghem, F. V., Hochepied, T., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46853-x · Cited by 9

Notch Inhibitors and BH3 Mimetics in T-Cell Acute Lymphoblastic Leukemia

Sergio, I., Varricchio, C., Squillante, F., Aeo, N. M. C., Campese, A. F., & Felli, M. P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312839 · Cited by 7

Targeting LMO2-induced autocrine FLT3 signaling to overcome chemoresistance in early T-cell precursor acute lymphoblastic leukemia

Tremblay, C. S., Saw, J., Yan, F., Boyle, J. A., Amarasinghe, O., Abdollahi, S., Vo, A. N. Q., Shields, B. J., Mayoh, C., McCalmont, H., et al. (2025) · Leukemia · doi:10.1038/s41375-024-02491-5 · Cited by 7

Novel Therapeutic Approaches in Pediatric Acute Lymphoblastic Leukemia

Marrapodi, M. M., Paola, A. D., Feo, G. D., Domenico, O. D., Martino, M. D., Argenziano, L., Falcone, M., Pinto, D. D., Rossi, F., & Pota, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311362 · Cited by 10

T-cell acute lymphoblastic leukemia: promising experimental drugs in clinical development

Thomas, X. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2161361 · Cited by 7

Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia

Scott, L. J. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00673-1 · Cited by 7

Genetic landscape of T cells identifies synthetic lethality for T-ALL

O’Meara, C. P., Guerri, L., Lawir, D.-F., Mateos, F., Iconomou, M., Iwanami, N., Soza‐Ried, C., Sikora, K., Siamishi, I., Giorgetti, O. B., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02694-x · Cited by 7

Sensitization effect of kaempferol from persimmon leaves on HepG2 hepatoma cells with ABT-199 resistance and its molecular mechanisms

Chen, L., Jiang, X., Gao, S., Liu, X., Gao, Y., Kow, A. S. F., Tham, C. L., & Lee, M. T. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1032069 · Cited by 7

RBP2 Promotes Adult Acute Lymphoblastic Leukemia by Upregulating BCL2

Wang, X., Zhou, M., Fu, Y., Sun, T., Chen, J., Qin, X., Yu, Y., Jia, J., & Chen, C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152142 · Cited by 6

Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia

Wu, X., Zhang, J., Chen, Q., Zhou, L., Li, M., Qiu, H., Sun, A., & Wu, D. (2020) · British Journal of Haematology · doi:10.1111/bjh.16622 · Cited by 7

Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment

Cowell, J. K., & Hu, T. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.30 · Cited by 6

Synergistic Effect of Venetoclax and Bendamustine in Early T-cell Precursor Acute Lymphoblastic Leukemia

NGUYEN, H. D. T., LE, T. M., LEE, D., Cho, H. J., LEE, J., Sohn, S. K., KIM, J. G., Ham, J. Y., MOON, J. H., Han, H. S., et al. (2024) · In Vivo · doi:10.21873/invivo.13624 · Cited by 6

Modern treatment approaches to adult acute T-lymphoblastic and myeloid/T-lymphoblastic leukemia: from current standards to precision medicine

Leoncin, M., Starza, R. L., Roti, G., Pagliaro, L., Bassan, R., & Mecucci, C. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000900 · Cited by 6

Venetoclax Use in Paediatric Haemato-Oncology Centres in Poland: A 2022 Survey

Bobeff, K. Ł., Pastorczak, A. K., Urbańska, Z., Balwierz, W. A., Juraszewska, E., Wachowiak, J., Derwich, K., Samborska, M., Kałwak, K., Dachowska-Kałwak, I., et al. (2023) · Children · doi:10.3390/children10040745 · Cited by 6

Discovery and optimization of (2-naphthylthio)acetic acid derivative as selective Bfl-1 inhibitor

Niu, P., Xu, H., & Fan, M. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129658 · Cited by 6

New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia

Paganelli, F., Lonetti, A., Anselmi, L., Martelli, A. M., Evangelisti, C., & Chiarini, F. (2019) · Advances in Biological Regulation · doi:10.1016/j.jbior.2019.100649 · Cited by 8

Pharmacotherapeutic management of T-cell acute lymphoblastic leukemia in adults: an update of the literature

Grunenberg, A., Sala, E., Kapp‐Schwoerer, S., & Viardot, A. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2033725 · Cited by 6

Venetoclax-Based Regimen in Refractory or Relapsed Pediatric Acute Lymphoblastic Leukemia

Zhang, L., Zhang, Z., Lu, A., Jia, Y., Huang, L., Zhang, L., & Zeng, H. (2025) · Acta Haematologica · doi:10.1159/000547080 · Cited by 5

Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 trial

Cao, H., Zhang, H., Zhang, Y., Hu, X.-H., Li, Y., Yang, Y., Zhang, Y.-M., Wu, B., Huang, Z.-Q., Huang, R., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00284-4 · Cited by 5

Pre-Clinical Evaluation of the Hypomethylating Agent Decitabine for the Treatment of T-Cell Lymphoblastic Lymphoma

Provez, L., Putteman, T., Landfors, M., Roels, J., Reunes, L., T’Sas, S., Loocke, W. V., Lintermans, B., Coninck, S. D., Thénoz, M., et al. (2023) · Cancers · doi:10.3390/cancers15030647 · Cited by 6

Investigating the response of paediatric leukaemia‐propagating cells to BCL‐2 inhibitors

Diamanti, P., Ede, B. C., Dace, P., Barendt, W. J., Cox, C. V., Hancock, J. P., Moppett, J. P., & Blair, A. (2020) · British Journal of Haematology · doi:10.1111/bjh.16773 · Cited by 5

T‐cell acute lymphoblastic leukemia: Current approach and future directions

Luskin, M. R., & DeAngelo, D. J. (2019) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.70 · Cited by 5

Venetoclax-based low-intensity chemotherapy in the salvage treatment of relapsed/refractory T-cell acute lymphoblastic leukemia

Xu, F., Bao, X., Huang, W. D., & Zhou, K. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01638-7 · Cited by 4

SOHO State of the Art Updates and Next Questions | Approach to Older Adults With Phildadelphia-Chromosome Negative Acute Lymphoblastic Leukemia

Shimony, S. O., & Luskin, M. R. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.10.011 · Cited by 4

A novel polyethylene glycol ( PEG )‐drug conjugate of Venetoclax, a Bcl‐2 inhibitor, for treatment of acute myeloid leukemia ( AML )

Ando, H., Murakami, Y., Eshima, K., & Ishida, T. (2021) · Cancer Reports · doi:10.1002/cnr2.1485 · Cited by 3

Thymic-Epithelial-Cell-Dependent Microenvironment Influences Proliferation and Apoptosis of Leukemic Cells

Patel, S. K., Zhdanovskaya, N., Sergio, I., Cardinale, A., Rosichini, M., Varricchio, C., Pace, E., Capalbo, C., Locatelli, F., Macone, A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031412 · Cited by 3

Mini-hyper-CVD plus venetoclax and navitoclax for relapsed/refractory acute lymphoblastic leukemia

Short, N. J., Kantarjian, H. M., Jain, N., Kadia, T. M., Senapati, J., Haddad, F., Maroun, M., Sasaki, K., Xiao, L., Huang, X., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016565 · Cited by 3

[Clinical efficacy and safety of venetoclax combined with multidrug chemotherapy in the treatment of 15 patients with relapsed or refractory early T-cell precursor acute lymphoblastic leukemia].

Kong, J. Y., Zong, L., Pu, Y., Liu, Y., Kong, X., Li, M. Y., Zhang, J., Song, B., Xue, S., Tang, X., et al. (2023) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2023.08.006 · Cited by 3

Venetoclax: A novel B-cell lymphoma-2 inhibitor for chronic lymphocytic leukemia and other hematologic malignancies

Olin, J. L., Griffiths, C. L., & Smith, M. B. (2017) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217718383 · Cited by 3

Subcellular Proteome Analysis Reveals Apoptotic Vulnerability of T‐Cell Acute Lymphoblastic Leukemia

Song, X., Wu, X., Zhang, Z., Cui, Z., Zheng, Y., & Sun, J. M. (2022) · BioMed Research International · doi:10.1155/2022/5504475 · Cited by 3

Evaluation of Novel Targets, Including CC-Chemokine Receptor 4, in Adult T-Cell Acute Lymphoblastic Leukemia/Lymphoma: A Mayo Clinic Clinical and Pathologic Study

Khurana, S., Heckman, M. G., Craig, F. E., Cochuyt, J. J., Greipp, P. T., Rahman, Z. A., Sproat, L. Z., Litzow, M. R., Foran, J. M., & Jiang, L. (2023) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2022-0482-oa · Cited by 3

The Effects of ABT-199 and Dihydroartemisinin Combination on Cell Growth and Apoptosis in Human U937 and KG-1 Cancer Cells

Nazmabadi, R., Pooladi, M., Amri, J., Darvish, M., Abbasi, Y., & Karami, H. (2024) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2024.25.1.343 · Cited by 3

Case report: Treatment of two cases of recurrent/refractory early T-cell precursor acute lymphoblastic leukemia with venetoclax combined with the CAG regimen

Jiang, Y., Ji, L., Jin, X., Wu, H., He, M., Shen, F., Xu, X., & Jiang, H. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1358161 · Cited by 3

Combination of venetoclax with CHG regimen in refractory/relapsed T-lymphoblastic lymphoma/acute lymphoblastic leukemia: a case series and literature review

Zhou, M., Yang, Y., Zhang, X., Jiao, Y., & Guo, Z. (2025) · Discover Oncology · doi:10.1007/s12672-025-03055-4 · Cited by 2

Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199

Chonghaile, T. N., Roderick, J. E., Glenfield, C., Ryan, J. A., Sallan, S. E., Silverman, L. B., Loh, M. L., Hunger, S. P., Wood, B. L., DeAngelo, D. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0353 · Cited by 276

Characterizing the role of BCL-2 family members as targets for anti-cancer therapy

Fortner, C. (2026) · doi:10.18725/oparu-60666

Therapeutic potential of BH3-mimetics and NK cell-mediated immunotherapy in T-ALL

Fortner, C., Niedermayer, A., Bäuerle, M. M., Wichert, M. C., Braun, C. J., Debatin, K., Vogler, M., Meyer, L. H., & Seyfried, F. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08698-x · Cited by 1

Identification of a New Targeted Therapy for T-Cell Acute Lymphoblastic Leukemia and Studies on Its Mechanism of Action

Shah, K., & Kazi, J. U. (2019) · Blood · doi:10.1182/blood-2019-129823

Identification of vulnerabilities for targeting BCL-2 family members in T-Cell Acute Lymphoblastic Leukemia

Fortner, C., Wichert, M. C., Niedermayer, A., Debatin, K., Meyer, L. H., & Seyfried, F. (2023) · Blood · doi:10.1182/blood-2023-177613